SEC Form 4 · accession 0000899243-17-016105
Aldeyra Therapeutics, Inc. · ALDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ben Bronstein
Director
Period of report
Jun 8, 2017
Accepted (ET)
Jun 12, 2017 · 5:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001341235
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.15 | Jun 8, 2017 | A | 17,776 | A | — | Jun 7, 2027 | Common Stock | 17,776 | 17,776 | D |
| Stock Option (Right to Buy)F2 | $5.15 | Jun 8, 2017 | A | 2,222 | A | — | Jun 7, 2027 | Common Stock | 2,222 | 2,222 | D |
| Stock Option (Right to Buy)F3 | $5.15 | Jun 8, 2017 | A | 1,481 | A | — | Jun 7, 2027 | Common Stock | 1,481 | 1,481 | D |
Explanation of responses
- F1Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
- F2Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
- F3Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Compensation Committee of the Board of Directors of the Issuer through the applicable vesting date.